#Canada #Toronto #Provigil #Nuvigil #Apotex

Apotex Acquires US Rights to PROVIGIL® and NUVIGIL®

In a major development for the pharmaceutical industry, Apotex Inc., Canada’s largest pharmaceutical company, has announced the acquisition of the United States rights to the widely used medications PROVIGIL and NUVIGIL. This acquisition was made by its affiliate, Nuvo Pharmaceuticals (Ireland) DAC, on January 9, 2025.

Overview of the Acquisition

This strategic step positions Apotex to significantly enhance its specialty business within the United States, a move that reflects the company's ongoing commitment to improvement in patient healthcare. With PROVIGIL and NUVIGIL now part of its extensive portfolio, which encompasses more than 550 generic and branded products across various therapeutic areas, Apotex aims to leverage its established distribution networks and commercial expertise to reach patients more effectively.

President & CEO Allan Oberman noted the importance of this acquisition as it not only supports Apotex’s growth strategy but also opens avenues for the company to extend its impact on the US market. He stated, "Acquiring the US rights to PROVIGIL and NUVIGIL marks a strategic milestone for Apotex and a significant initial step in growing our US specialty business."

The Importance of PROVIGIL and NUVIGIL

PROVIGIL (modafinil) and NUVIGIL (armodafinil) are both indicated for improving wakefulness in adults suffering from excessive sleepiness associated with conditions such as narcolepsy, obstructive sleep apnea (OSA), or shift work disorder. These medications are crucial in helping patients manage their daily lives more effectively. They're routinely prescribed by healthcare professionals, including psychiatrists, internists, and sleep specialists, who recognize the need for effective treatments in this area.

Christine Baeder, the President of Apotex Corp. (the company’s US affiliate), emphasized the focus on addressing patients' needs. She remarked, "PROVIGIL and NUVIGIL address critical needs for patients experiencing excessive sleepiness. Leveraging our world-class commercial team, established distribution networks, and expertise in the US market, we are well-positioned to ensure these medications continue to reach patients effectively."

Future Looks Bright

With this acquisition, Apotex is not only enhancing its product range but is also reinforcing its commitment to improve patient care across the Americas. This move aligns with the company’s Journey of Health growth strategy and signifies its long-term objective of expanding its presence in the US pharmaceutical market.

Apotex has established itself as a trusted health provider globally, and this strategic acquisition will undoubtedly play a pivotal role in its quest to continue delivering affordable and innovative medicines.

For more information about APOTEX’s commitment to healthcare and its diverse product portfolio, visit www.apotex.com.